Trial · NCT05330325
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325, Phase 3, Active not recruiting, Novo Nordisk A/S
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow. Trials, record NCT05330325. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05330325
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
- NCT number
- NCT05330325
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 412 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- SGA, Turner Syndrome, Noonan Syndrome, ISS
- Interventions
- Somapacitan, Norditropin®
- First posted
- 2022-04-15
- Last updated
- 2026-06-12
- Other registries' IDs
- eudract:2021-005607-13
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Height velocity reported separately for small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS) and idiopathic short stature (ISS) | From baseline (week 0) to visit 7 (week 52) | Measured in centimeter per year (cm/year) |
| Secondary | Change in Height standard deviation scores (SDS) reported separately for SGA, TS, NS and ISS | From baseline (week 0) to visit 7 (week 52) | Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline. |
| Secondary | Change in Height Velocity SDS reported separately for SGA, TS, NS and ISS | From baseline (week 0) to visit 7 (week 52) | Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline. |
| Secondary | Change in bone age reported separately for SGA, TS and NS | From baseline (week 0) to visit 7 (week 52) | Measured in ratio |
| Secondary | Change in bone age for ISS | From screening (visit 1) to visit 7 (week 52) | Measured in ratio |
| Secondary | Change in insulin-like growth factor 1 (IGF-1) SDS reported separately for SGA, TS, NA and ISS | From baseline (week 0) to visit 7 (week 52). | Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline. |
| Secondary | Change in insulin-like growth factor binding protein-3 (IGFBP-3) SDS reported separately for SGA, TS, NA and ISS | From baseline (week 0) to visit 7 (week 52). | Measured in score. Positive score indicates that the value is closer to or above the reference population compared to baseline. |
| Secondary | Change in fasting plasma glucose reported separately for SGA, TS, NS and ISS | From screening (visit 1) to visit 7 (week 52) | Measured in millimoles per litre (mmol/L) |
| Secondary | Change in homeostatic model assessment-B (HOMA-B) reported separately for SGA, TS, NS and ISS | From screening (visit 1) to visit 7 (week 52) | Measured in percentage (%) |
| Secondary | Change in homeostatic model assessment of insulin resistance (HOMAIR) reported separately for SGA, TS, NS and ISS | From screening (visit 1) to visit 7 (week 52) | Measured in % |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05330325
GET https://conductscience.org/api/trials/v1/NCT05330325/registered